We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Flow-Through Testing Technology Expanded for HIV Diagnosis

By HospiMedica staff writers
Posted on 24 Dec 2007
A new range of rapid HIV testing products is being produced utilizing a new scientific test platform.

The core technology platform, which is the basis a new generation of infectious disease testing products, includes a rapid flow-through diagnostic device, assay, and multi-functional buffer.

The rapid diagnostic tests were developed by MedMira (Halifax, Canada) and are to be sold by the German company Vitest (Hennigsdorf, Germany). This is the first shipment of MedMira's private label product to a distributor in Europe. Under the private label agreement, Vitest will market and sell the new product under the Vitest brand and it will be a part of the Vitest suite of rapid testing products.

"Our rapid flow-through technology platform has an endless list of potential applications, for which our current product pipeline has barely scratched the surface,” said Hermes Chan, president and CEO of MedMira. "Our strategic goals involve the pursuit of a wide range of opportunities to diversify not only our own product portfolio, but also to make available a private label or OEM [original equipment manufacturer] capability to fill the needs of our partners. We are pleased to welcome Vitest as our first partner in this endeavor.”

MedMira is a developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics, and individuals worldwide with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal, MiraWell, MiraCare, and Multiplo brands. MedMira's rapid HIV test has achieved regulatory approvals in Canada, the United States, China, and the European Union.

The Maple Biosciences division of MedMira develops and commercializes diagnostic instruments based on two new biosensor-based technology platforms. Solutions developed by The Maple Biosciences division of MedMira enable routine laboratory tests to be performed in minutes, increasing laboratory automation, and streamlining the diagnosis of multiple conditions and diseases.


Related Links:
MedMira
Vitest

New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
Automated Blood Typing System
IH-500 NEXT
New
Malaria Rapid Test
OnSite Malaria Pf/Pan Ag Rapid Test
New
Free Human Prostate-Specific Antigen CLIA
LIAISON fPSA

Latest Industry News

Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests